Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.74 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.74 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.74 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.74 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.74 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.74 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.74 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.74 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26498639 | 0.95 | CYP1A1 (0.83) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL26498789 | 0.95 | CYP1A1 (0.83) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL26498734 | 0.95 | CYP1A1 (0.83) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2407878 | 0.95 | CYP1A1 (0.74) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL28102064 | 0.89 | CYP1A2 (0.72) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL28102062 | 0.88 | ABL1 (0.73) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL7241617 | 0.87 | CYP1A1 (0.57) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL29698794 | 0.87 | CYP1A1 (0.57) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL23743214 | 0.85 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2545199 | 0.85 | ABCB1 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0213893-B1 | Photopolymerisable compositions containing substituted pyrylium salts as photoinitiators; and novel pyrylium salts for use therein | LOCTITE IRELAND LTD (IE) | 1993-11-10 | — | — | EP | claimed |
| US-11858952-B2 | Compound and color conversion film comprising same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210347790-A1 | COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME | LG CHEM, LTD. (KR) | 2021-11-11 | — | — | US | disclosed |
| CN-1802374-A | White-emitting compounds, process for the production thereof, and white-emitting devices | HIROSE ENGINEERING CO LTD (JP) | 2006-07-12 | — | — | CN | disclosed |
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | disclosed |
| EP-0559742-A1 | HERBICIDAL OXAZINE ETHERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347790-A1 | COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME | BLVRB, CDYL, CRY1 | CYP1A1 651/4885CYP1B1 309/4885CYP1A2 477/4885 |
| US-11858952-B2 | Compound and color conversion film comprising same | BLVRB, CDYL, CRY1 | CYP1A1 651/4885CYP1B1 309/4885CYP1A2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.